The once-daily human glucagon-like peptide-1 (GLP-1) analog liraglutide improves postprandial glucose levels in type 2 diabetes patients

被引：0
|
作者：
Anne Flint
Christoph Kapitza
Charlotte Hindsberger
Milan Zdravkovic
机构：
[1] Novo Nordisk A/S,
[2] Novo Nordisk A/S,undefined
[3] PROFIL Institut für Stoffwechselforschung GmbH,undefined
来源：
Advances in Therapy | 2011年 / 28卷
关键词：
exenatide; gastric emptying; incretin; insulin; type 2 diabetes mellitus;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：213 / 226
页数：13
相关论文
共 50 条
  • [41] Early use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in Type 2 diabetes
    Ross, Stuart A.
    Ballantine, Jane
    CURRENT MEDICAL RESEARCH AND OPINION, 2013, 29 (12) : 1617 - 1626
  • [42] The low level of glucagon-like peptide-1 (glp-1) is a risk factor of type 2 diabetes mellitus
    Lastya A.
    Saraswati M.R.
    Suastika K.
    BMC Research Notes, 7 (1)
  • [43] Medication adherence to injectable glucagon-like peptide-1 (GLP-1) receptor agonists dosed once weekly vs once daily in patients with type 2 diabetes: A meta-analysis
    Weeda, Erin R.
    Muraoka, Alyssa K.
    Brock, Matthew D.
    Cannon, Jessica M.
    INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2021, 75 (09)
  • [44] Effects of the once-daily human GLP-1 analogue liraglutide on appetite and energy intake in type 2 diabetes
    Horowitz, M.
    Flint, A.
    Doran, S.
    Rasmussen, M. F.
    Kapitza, C.
    Andreasen, A. H.
    Jones, K. L.
    Zdravkovic, M.
    Chapman, I. M.
    DIABETOLOGIA, 2008, 51 : S355 - S355
  • [45] Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide
    Lau, Jesper
    Bloch, Paw
    Schaffer, Lauge
    Pettersson, Ingrid
    Spetzler, Jane
    Kofoed, Jacob
    Madsen, Kjeld
    Knudsen, Lotte Bjerre
    McGuire, James
    Steensgaard, Dorte Bjerre
    Strauss, Holger Martin
    Gram, Dorte X.
    Knudsen, Sanne Moller
    Nielsen, Flemming Seier
    Thygesen, Peter
    Reedtz-Runge, Steffen
    Kruse, Thomas
    JOURNAL OF MEDICINAL CHEMISTRY, 2015, 58 (18) : 7370 - 7380
  • [46] The glucagon-like peptide-1 (GLP-1) analog liraglutide attenuates renal fibrosis (vol 131, pg 102, 2018)
    Li, Ya-Kun
    Ma, Dong-Xia
    Wang, Zhi-Min
    Hu, Xiao-Fan
    Li, Shang-Lin
    Tian, Hong-Zhe
    Wang, Meng-Jun
    Shu, Yan-Wen
    Yang, Jun
    PHARMACOLOGICAL RESEARCH, 2018, 135 : 269 - 270
  • [47] Glucagon-like Peptide-1 (GLP-1): 25 Years Incentive for Diabetes research
    Nauck, M. A.
    DIABETOLOGIE UND STOFFWECHSEL, 2012, 7 (05) : 367 - 372
  • [48] Normalisation of fasting and postprandial blood glucose with graded doses of glucagon-like peptide 1 (GLP-1) in Type 2 diabetic patients
    Meier, JJ
    Salmen, S
    Götze, O
    Baller, B
    Holst, JJ
    Schmidt, WE
    Nauck, MA
    Gallwitz, B
    DIABETOLOGIA, 2002, 45 : A215 - A215
  • [49] Glucagon-like peptide 1 (GLP-1) in the treatment of diabetes
    Nauck, MA
    HORMONE AND METABOLIC RESEARCH, 2004, 36 (11-12) : 852 - 858
  • [50] Effects of the long-acting human glucagon-like peptide-1 analog liraglutide on plasma omentin-1 levels in patients with type 2 diabetes mellitus
    Yan, Pijun
    Li, Ling
    Yang, Mengliu
    Liu, Dongfang
    Liu, Hua
    Boden, Guenther
    Yang, Gangyi
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2011, 92 (03) : 368 - 374
12345